Xingang Li | harmacology | Best Research Article Award

Posted on by Pencis

Prof. Xingang Li | pharmacology | Best Research Article Award 

Prof. Xingang Li, Department of Pharmacy, Beijing Friendship Hospital, China

Prof. Xingang Li is the Deputy Director of the Pharmacy Department at Beijing Friendship Hospital, China, where he also serves as a Chief Pharmacist, Professor, and Ph.D. Supervisor. An expert in quantitative pharmacology and genetic pharmacology, Prof. Li has published over 50 articles in top-tier journals, with more than 1000 citations and an H-index of 20. He is an External Expert at the National Center for Drug Evaluation, a member of multiple prestigious pharmacological committees, and a reviewer for leading journals such as Biomaterials and Clin Transl Med. His research focuses on personalized medicine, drug delivery systems, and epigenetic influences on pharmacodynamics.

Profile:

Orcid Profile

🏥 Current Positions:

Prof. Li Xingang serves as the Deputy Director of the Pharmacy Department at Beijing Friendship Hospital, where he is also the Chief Pharmacist. As a Professor and Ph.D. Supervisor, he is instrumental in nurturing future generations of pharmacists and researchers. His leadership role involves overseeing advanced pharmacological practices, mentoring young scientists, and ensuring cutting-edge drug evaluation and management systems. With a strong emphasis on precision medicine, Prof. Li combines clinical expertise and research excellence to address pressing healthcare challenges.

📚 Academic Background:

Prof. Li has an extensive academic background, which underpins his outstanding contributions to quantitative pharmacology and genetic pharmacology. His role as an External Expert at the National Center for Drug Evaluation and Review Expert for the Beijing Science and Technology Plan Project showcases his authority in the field. His memberships in prestigious committees, such as the Quantitative Pharmacology Committee of the Chinese Pharmacological Society and the Epigenetics Committee, reflect his deep commitment to advancing pharmaceutical sciences.

🧪 Research Interests and Achievements:

Quantitative Pharmacology: Prof. Li has a keen interest in developing predictive models to optimize drug efficacy and safety, leveraging mathematical frameworks to personalize treatment.

Genetic Pharmacology: His research focuses on exploring genetic factors that influence drug metabolism and efficacy, aiming to enhance personalized medicine approaches.

Prof. Li has successfully led over ten major projects, including initiatives funded by the Ministry of Science and Technology, the National Natural Science Foundation, and the Beijing Science and Technology Plan. These projects address critical areas like drug delivery systems, personalized pharmacotherapy, and genetic determinants of drug response.

🖋️ Publication Achievements:

Prof. Li’s academic rigor is evident in his extensive publication record, with over 50 articles in Q1 journals such as Nano Letters, Acta Pharmacologica Sinica, and Phytomedicine. His works have been cited more than 1000 times, and he holds an impressive H-index of 20, reflecting his impact on the scientific community. His publications explore innovative drug delivery systems, genetic biomarkers, and clinical pharmacokinetics, contributing significantly to global pharmacological advancements.

🏆 Scholarships and Awards:

Prof. Li has received numerous accolades for his contributions:

  • Servier Young Hospital Pharmacy Award, China Pharmaceutical Society
  • Outstanding Pharmacist Award, Beijing Pharmaceutical Society
  • Recognized for Outstanding Papers and groundbreaking research, reflecting his excellence in clinical pharmacy and translational research.

🧑‍🔬 Professional Associations and Editorial Roles:

Prof. Li is actively involved in professional organizations, including the Chinese Pharmacological Society and the China Pharmaceutical Education Association. He serves as an Editorial Board Member for journals such as China Hospital Pharmacy Evaluation and Analysis and Chinese Pharmacy, ensuring the dissemination of high-quality research.

As a Reviewer for prestigious journals like Biomaterials and Clin Transl Med, he evaluates cutting-edge studies in pharmacology, bioinformatics, and materials science, further contributing to his field’s knowledge base.

💻 Bioinformatics and Laboratory Experience:

Prof. Li integrates bioinformatics tools into his research to analyze complex datasets and identify genetic markers associated with drug response. His laboratory is equipped with advanced technologies for pharmacokinetic modeling, epigenetic profiling, and drug formulation analysis, enabling groundbreaking discoveries.

🎓 Training, Workshops, and Oral Presentations:

Prof. Li regularly participates in international conferences, presenting his research findings and engaging with global experts. His oral presentations at prestigious forums highlight advancements in therapeutic drug monitoring (TDM), anesthesiology pharmacy, and intravenous preparation management, solidifying his reputation as a thought leader.

✅ Tasks Completed as a Researcher:

Prof. Li has successfully completed tasks ranging from designing clinical trials to publishing high-impact research. His ability to translate laboratory findings into practical solutions for patient care exemplifies his commitment to improving healthcare outcomes.

🌟 Success Factors and Key Contributions:

Prof. Li’s success stems from his:

  • Collaborative approach in multidisciplinary projects
  • Innovative methodologies in drug evaluation and genetic research
  • Dedication to mentoring young professionals and fostering academic growth

🔬 Ongoing Research Projects:

His current projects delve into:

  • Advanced drug delivery systems to enhance treatment efficacy
  • Epigenetic influences on pharmacodynamics
  • Personalized medicine approaches using genetic profiling

🔍 Conclusion:

Prof. Li Xingang is a distinguished leader in the field of pharmacology, whose contributions span clinical excellence, innovative research, and impactful publications. His work in quantitative and genetic pharmacology, combined with his dedication to mentoring and professional engagement, sets him apart as a visionary in healthcare. His achievements and ongoing endeavors continue to shape the future of precision medicine and pharmacological sciences.

Top Notable Publications:

1. Immune-Related Colitis Induced by Camrelizumab: A Case Report

Authors: Xingang Li

Journal: Journal of Inflammation Research

Year: 2023

2. Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients

Authors: Xingang Li

Journal: European Journal of Hospital Pharmacy: Science and Practice-

Year: 2023

3. Association of Alcohol Drinking and Helicobacter pylori Infection: A Meta-analysis

Authors: Xingang Li

Journal: Journal of Clinical Gastroenterology

Year: 2023

4. Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

Authors: Xingang Li

Journal: European Journal of Hospital Pharmacy: Science and Practice

Year: 2022

5. Association between GNAQ Gene DNA Methylation and Vascular Recurrence in Patients with Acute Ischemic Stroke or Transient Ischemic Attack

Authors: Xingang Li

Journal: Cerebrovascular Diseases (Basel, Switzerland)

Year: 2022

6. Impact of Azithromycin on Forsythiaside Pharmacokinetics in Rats: A Population Modeling Method

Authors: Xingang Li

Journal: Current Medical Science

Year: 2022

7. Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients

Authors: Xingang Li

Journal: Annals of Translational Medicine

Year: 2022

8. Development of a multivariable clinical prediction model for liposomal doxorubicin-induced cardiotoxicity in adult breast cancer patients: A retrospective multicenter study

Authors: Xingang Li

Journal: Annals of Translational Medicine

Year: 2022

9. Population pharmacokinetics of methotrexate in pediatric patients with acute lymphoblastic leukemia and malignant lymphoma

Authors: Xingang Li

Journal: Xenobiotica

Year: 2022

10. The clinical population pharmacokinetics, metabolomics, and therapeutic analysis of alkaloids from Alstonia scholaris leaves in acute bronchitis patients

Authors: Xingang Li

Journal: Phytomedicine

Year: 2022

Lakshmanan Loganathan | Pharmacogenomics | Best Researcher Award

Posted on by Pencis

Dr. Lakshmanan Loganathan | Pharmacogenomics | Best Researcher Award 

Dr. Lakshmanan Loganathan, Micro Health Laboratories, India

Dr. Lakshmanan Loganathan is a Scientist ‘C’ and Scientific Coordinator at Micro Health Laboratories, India, with over nine years of research experience and three years in the diagnostics field. Specializing in computational biology, drug design, microbial genomics, medical genetics, and pharmacogenomics, he has successfully led numerous research projects and developed innovative methodologies. Dr. Loganathan has expertise in structure-based and ligand-based drug design, molecular dynamics, RT-PCR, and SNP studies. With a strong background in computational skills, project management, and scientific communication, he is dedicated to advancing human health through cutting-edge research.

Profile:

Scopus Profile 

Orcid Profile

Google Scholar

 

Education Qualification:

 

Dr. Lakshmanan Loganathan holds a Ph.D. in Bioinformatics from Alagappa University, Karaikudi (2022), where he conducted a highly commendable thesis on RAS and CYP gene polymorphisms in anti-hypertensive treatment. He also earned a PG Diploma in Structural Pharmacogenomics (2015) with the university’s top rank and an M.Sc. in Bioinformatics (2014), both from Alagappa University, achieving high commendations for his innovative research in molecular docking and genomics. Additionally, he holds a B.Sc. in Microbiology from Yadava Arts & Science, Madurai (2012).

Professional Experiences:

Dr. Lakshmanan Loganathan is a Scientist ‘C’ and Scientific Coordinator at Micro Health Laboratories in India, where he has been instrumental in designing and implementing innovative experiments to develop cost-effective diagnostic tests since November 2022. His career includes extensive experience as a Research Scholar at Alagappa University, where he published multiple academic papers and contributed to collaborative research projects. Previously, he held positions such as Lab Manager and Research Associate at Rainbow Children’s Medicare, where he assisted in developing a molecular genetics laboratory and managed the NABL accreditation process. His role as Manager of Lab Operations at SciGene Diagnostics involved overseeing various departments and establishing effective communication with key stakeholders. With a strong background in research, diagnostics, and technical documentation, Dr. Loganathan is dedicated to advancing medical science through innovative methodologies and quality assurance processes.

 Academic Merit & Awards :

Dr. Lakshmanan Loganathan has made significant contributions to the field of bioinformatics, receiving numerous accolades throughout his academic and professional journey. He participated in the UGC-Resource Networking Summer Training Program at Jawaharlal Nehru University in 2013 and was honored with a certificate of appreciation from the Prime Minister of India for his involvement in the Republic Day Parade in 2014. In recognition of his outstanding academic performance during his M.Sc. at Alagappa University, he was named the “Meritorious Student of the Year” for 2013 and received several scholarships, including the PMT & VOC merit scholarship. During his Ph.D. tenure from 2015 to 2020, he was awarded fellowships from DBT, MHRD, and RUSA. Dr. Loganathan also received the special prize for best poster presentation at the ICCIPS-2019 conference and was recognized as the “INTERNATIONAL BEST RESEARCHER” in bioinformatics at the IISTAC-2022 congress.

Thesis work:

Dr. Lakshmanan Loganathan has a robust academic background in bioinformatics, with a focus on microbiology and pharmacogenomics. He completed a six-month post-M.Sc. dissertation on “Identification of Vibrio harveyi through 16s rRNA sequencing” under the guidance of Dr. P. Srinivasan at Alagappa University. Additionally, he undertook a six-month postgraduate diploma project on “Identification of potent inhibitors against NS3 helicase protein of Zika virus,” supervised by Dr. M. Karthikeyan. Dr. Loganathan’s Ph.D. thesis, titled “Role of RAS and CYP Gene Polymorphisms in Anti-Hypertensive Treatment,” also under the supervision of Dr. Karthikeyan, was highly commended for its contributions to pharmacogenomics and computational studies.

Top Notable Publications:

Renin and CYP P450 gene variations significantly associated with essential hypertension: A prospective pharmacogenomics study

Authors: Loganathan, L., Carlus, S.J., Muthusamy, K.

Year: 2024

Journal: Gene Reports

Volume: 37

Article Number: 102023

Citations: 0

HTNpedia: A Knowledge Base for Hypertension Research

Authors: Loganathan, L., Jeyaraman, J., Muthusamy, K.

Year: 2024

Journal: Combinatorial Chemistry and High Throughput Screening

Volume: 27(5)

Pages: 745–753

Citations: 0

In silico prediction, molecular modeling, and dynamics studies on the targeted next-generation sequencing identified genes underlying congenital heart disease in Down syndrome patients

Authors: Carlus, F.H., Sujatha, L.B., Kumar, A.G., Muthusamy, K., Carlus, S.J., et al.

Year: 2023

Journal: Annals of Pediatric Cardiology

Volume: 16(4)

Pages: 266–275

Citations: 0

Theoretical investigation on known renin inhibitors and generation of ligand-based pharmacophore models for hypertension treatment

Authors: Loganathan, L., Sankar, J., Rajendran, K., Muthusamy, K.

Year: 2023

Journal: Journal of Biomolecular Structure and Dynamics

Citations: 1

Targeting renin receptor for the inhibition of renin angiotensin aldosterone system: An alternative approach through in silico drug discovery

Authors: Loganathan, L., Briget Kuriakose, B., Lobelle Sampayan, E., Muthusamy, K.

Year: 2022

Journal: Computational and Theoretical Chemistry

Volume: 1208

Article Number: 113541

Citations: 1

An in silico analysis of the impact of POLE mutations on cladribine docking

Authors: Loganathan, L., Al-Haidose, A., Ganesh Kumar, A., Carlus, S.J., Abdallah, A.M.

Year: 2022

Journal: European Review for Medical and Pharmacological Sciences

Volume: 26(20)

Pages: 7580–7593

Citations: 3

Mechanistic insights on nsSNPs on binding site of renin and cytochrome P450 proteins: A computational perceptual study for pharmacogenomics evaluation

Authors: Loganathan, L., Kuriakose, B.B., Mushfiq, S., Muthusamy, K.

Year: 2021

Journal: Journal of Cellular Biochemistry

Volume: 122(10)

Pages: 1460–1474

Citations: 17

In silico drug designing for the identification of promising antagonist hit molecules against bradykinin receptor

Authors: Selvaraj, M., Loganathan, L., Kumar Thirumalaisamy, P., Lobelle Sampayan, E., Muthusamy, K.

Year: 2021

Journal: Computational and Theoretical Chemistry

Volume: 1202

Article Number: 113334

Citations: 0

Virtual screening assisted discovery of novel natural products to inhibit the catalytic mechanism of Mycobacterium tuberculosis InhA

Authors: Jayaraman, M., Loganathan, L., Muthusamy, K., Ramadas, K.

Year: 2021

Journal: Journal of Molecular Liquids

Volume: 335

Article Number: 116204

Citations: 21

Computational study on cross-talking cancer signalling mechanism of ring finger protein 146, AXIN and Tankyrase protein complex

Authors: Loganathan, L., Natarajan, K., Muthusamy, K.

Year: 2020

Journal: Journal of Biomolecular Structure and Dynamics

Volume: 38(17)

Pages: 5173–5185

Citations: 7